December 22, 2010 - 5:02 p.m.
Gilead Terminates Phase III Clinical Trial of Ambrisentan in Patients with Idiopathic Pulmonary Fibrosis
Printer Friendly Version 
December 20, 2010 - 8:33 a.m.
Gilead Sciences to Acquire Arresto Biosciences for $225 Million
Printer Friendly Version 
December 16, 2010 - 4:17 p.m.
Department of Justice Declines to Intervene in Lawsuit against Gilead Sciences Regarding Ranexa(R)
Printer Friendly Version 
November 30, 2010 - 4:32 p.m.
Gilead Sciences to Present at the NASDAQ OMX 25th Investor Program
Printer Friendly Version 
November 23, 2010 - 4:32 p.m.
Gilead Sciences to Present at the 22nd Annual Piper Jaffray Healthcare Conference on Tuesday, November 30
Printer Friendly Version 
November 23, 2010 - 8:32 a.m.
Gilead Sciences Submits New Drug Application to U.S. FDA for Once-Daily Single-Tablet Regimen of Truvada(R) and TMC278 for HIV
Printer Friendly Version 
November 05, 2010 - 8:31 a.m.
Dr. Paul Berg to Retire from Gilead Sciences' Board of Directors
Printer Friendly Version 
November 04, 2010 - 4:32 p.m.
Gilead Sciences to Present at the 2010 CreditSuisse Healthcare Conference on Thursday, November 11
Printer Friendly Version 
October 30, 2010 - 9:02 a.m.
Viread(R) for Hepatitis B Maintains Antiviral Suppression with No Development of Resistance Through Four Years of Treatment
Printer Friendly Version 
October 30, 2010 - 9:01 a.m.
Gilead's Investigational Hepatitis C Compounds GS 9190 and GS 9256 in Combination with Standard of Care Therapies Achieve Substantial Viral Suppression in Phase II Study
Printer Friendly Version 
October 21, 2010 - 11:52 a.m.
Gilead's Cayston(R) Superior to Tobramycin Inhalation Solution in Six-Month Head-to-Head Cystic Fibrosis Study
Printer Friendly Version 
October 19, 2010 - 4:07 p.m.
Gilead Sciences Announces Third Quarter 2010 Financial Results
Printer Friendly Version 
October 12, 2010 - 4:31 p.m.
Gilead Sciences to Release Third Quarter 2010 Financial Results on Tuesday, October 19, 2010
Printer Friendly Version 
September 13, 2010 - 4:32 p.m.
Gilead Sciences to Present at the UBS Global Life Sciences Conference on Monday, September 20
Printer Friendly Version 
September 13, 2010 - 11:19 a.m.
Gilead's Single-Tablet "Quad" HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase II Study
Printer Friendly Version 
September 08, 2010 - 4:32 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
September 03, 2010 - 4:04 a.m.
Gilead Sciences Submits European Marketing Application for Once-Daily Single-Tablet Regimen of Truvada(R) and TMC278 for the Treatment of HIV Infection
Printer Friendly Version 
September 01, 2010 - 8:33 a.m.
Gilead Provides Update on $5 Billion Stock Repurchase Program
Printer Friendly Version 
August 19, 2010 - 7:58 p.m.
Gilead Sciences Announces Notification of ANDA Filing for Hepsera(R)
Printer Friendly Version 
July 30, 2010 - 4:31 p.m.
Gilead Closes Sale of $2.2 Billion of Convertible Senior Notes
Printer Friendly Version 
July 27, 2010 - 8:31 a.m.
Gilead Prices $2.2 Billion of Convertible Senior Notes; Company to Repurchase $1 Billion in Common Stock
Printer Friendly Version 
July 26, 2010 - 7:07 a.m.
Gilead to Offer $2.2 Billion of Convertible Senior Notes; Company to Repurchase $1 Billion in Common Stock
Printer Friendly Version 
July 20, 2010 - 4:07 p.m.
Gilead Sciences Announces Second Quarter 2010 Financial Results
Printer Friendly Version 
July 14, 2010 - 6:11 p.m.
Gilead Sciences Files Patent Infringement Lawsuit Against Lupin Limited
Printer Friendly Version 
July 13, 2010 - 5:31 p.m.
Gilead Sciences to Release Second Quarter 2010 Financial Results on Tuesday, July 20, 2010
Printer Friendly Version 
June 25, 2010 - 8:32 a.m.
Gilead Sciences to Acquire CGI Pharmaceuticals for up to $120 Million
Printer Friendly Version 
June 18, 2010 - 12:37 p.m.
Gilead's Head-to-Head Study of Cayston(R) Versus Tobramycin Inhalation Solution in Cystic Fibrosis Patients Achieves Co-Primary Efficacy Endpoint of Non-Inferiority
Printer Friendly Version 
June 10, 2010 - 8:32 p.m.
Gilead Sciences Announces Notification of ANDA Filing for Ranexa(R)
Printer Friendly Version 
June 09, 2010 - 4:31 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
June 08, 2010 - 4:32 p.m.
John G. McHutchison, MD, to Join Gilead Sciences as Senior Vice President, Liver Disease Therapeutics
Printer Friendly Version 
June 04, 2010 - 8:32 a.m.
Gilead Sciences and ADAP Crisis Task Force Announce New Initiatives to Support AIDS Drug Assistance Programs (ADAPs)
Printer Friendly Version 
June 02, 2010 - 4:32 p.m.
Gilead Sciences to Present at the Jefferies 2010 Global Life Sciences Conference on Wednesday, June 9
Printer Friendly Version 
May 27, 2010 - 4:31 p.m.
Gilead Sciences to Present at the Sanford C. Bernstein 26th Annual Strategic Decisions Conference on Thursday, June 3
Printer Friendly Version 
May 19, 2010 - 4:31 p.m.
Gilead Sciences to Present at the 2010 Citi Investment Research Global Health Care Conference on Wednesday, May 26
Printer Friendly Version 
May 11, 2010 - 8:33 a.m.
Gilead Announces $5 Billion Share Repurchase Program
Printer Friendly Version 
May 06, 2010 - 4:32 p.m.
Gilead Sciences to Present at the Banc of America Merrill Lynch 2010 Healthcare Conference on Thursday, May 13
Printer Friendly Version 
April 27, 2010 - 8:34 a.m.
Gilead Finalizes Selection of Bioequivalent Formulation for the Fixed-Dose Regimen of Truvada(R) and Tibotec Pharmaceuticals' TMC278
Printer Friendly Version 
April 20, 2010 - 4:07 p.m.
Gilead Sciences Announces Record First Quarter 2010 Financial Results
Printer Friendly Version 
April 20, 2010 - 8:52 a.m.
Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada(R) and Tibotec Pharmaceuticals' TMC278
Printer Friendly Version 
April 19, 2010 - 8:32 p.m.
Gilead Terminates Phase II Clinical Trial of GS 9450 in Patients With Chronic Hepatitis C
Printer Friendly Version 
April 13, 2010 - 4:19 p.m.
Gilead Sciences to Release First Quarter 2010 Financial Results on Tuesday, April 20, 2010
Printer Friendly Version 
April 12, 2010 - 4:17 p.m.
Gilead Initiates Phase III Clinical Program Evaluating Single-Tablet, Once-Daily "Quad" Regimen for HIV
Printer Friendly Version 
March 17, 2010 - 4:32 p.m.
Gilead Sciences to Present at the Barclays Capital 2010 Global Healthcare Conference on Wednesday, March 24
Printer Friendly Version 
March 04, 2010 - 4:33 p.m.
Gilead Sciences to Present at the Cowen and Company 30th Annual Health Care Conference on Thursday, March 11
Printer Friendly Version 
February 22, 2010 - 7:15 p.m.
U.S. Food and Drug Administration Approves Cayston(R) (Aztreonam for Inhalation Solution) for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients with Pseudomonas Aeruginosa
Printer Friendly Version 
February 17, 2010 - 11:04 a.m.
Gilead's Single-Tablet "Quad" Regimen for HIV Achieves a High Rate of Virologic Suppression in Phase II Study
Printer Friendly Version 
February 02, 2010 - 4:32 p.m.
Gilead Sciences to Present at the 12th Annual BIO CEO Investor Conference on Tuesday, February 9
Printer Friendly Version 
January 29, 2010 - 8:33 a.m.
Gilead Announces Share Repurchase Program
Printer Friendly Version 
January 28, 2010 - 4:33 p.m.
Per Wold-Olsen Joins Gilead Sciences' Board of Directors
Printer Friendly Version 
January 27, 2010 - 9:22 p.m.
Gilead Sciences Announces Notification of ANDA Filing for Viread®
Printer Friendly Version 
January 26, 2010 - 4:09 p.m.
Gilead Sciences Announces Record Fourth Quarter and Full Year 2009 Financial Results
Printer Friendly Version 
January 19, 2010 - 4:32 p.m.
Gilead Sciences to Release Fourth Quarter and Year End 2009 Financial Results on Tuesday, January 26, 2010
Printer Friendly Version 
January 06, 2010 - 8:34 a.m.
Phase II Clinical Trial of Gilead's Investigational Integrase-Based, Once-Daily, Fixed-Dose "Quad" Regimen Meets 24-Week Primary Objective
Printer Friendly Version 
January 04, 2010 - 4:33 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
NASDAQ (US Dollar)
$66.25
 Stock is Up 0.32 (0.49%)
Data as of 04/24/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote